U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07719946) titled 'To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers' on July 10.
Brief Summary: Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant. The standard dose of this medicine is 50 mg per kg of the patient's weight given on the 3rd and the 4th day. However, using this medicine at this dose of 50 mg / kg for 2 days is associated with certain problems such as susceptibility to infections and delay in the recovery of the immune system after stem cell transplant. There...